On the 21st, the government announced the guidelines for the public disclosure of expenditure reports on the legitimate financial benefits paid by pharmaceutical and medical device companies to doctors and pharmacists that will be disclosed in December.

The guidelines stipulate the detailed schedule, content, and method for disclosure of the economic benefit expenditure report prepared by companies as of the fiscal year 2023, per the amendments to the Pharmaceutical Affairs Act and the Medical Device Act, made on July 20, 2021.

Under the current law, the legally permissible economic benefits that can be provided are the provision of physical products, support for conferences, support fo